About OXiGENE
OXiGENE is a biopharmaceutical company whose mission is finding (via discovery or in-licensing) and developing new and improved therapeutics that address the significant unmet medical needs of patients with cancer and eye disease.

Back to Top

ZYBRESTAT™ (fosbretabulin, formerly known as combretastatin/CA4P)
ZYBRESTAT leads a novel class of drug candidates called vascular disrupting agents (VDAs). ZYBRESTAT is currently being evaluated in a pivotal registration sutdy as a potential treatment for anaplastic thyroid cancer, a highly aggressive and lethal malignancy. ZYBRESTAT attacks the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels. The drug triggers a change in the shape of the endothelial cells lining these blood vessels, in turn, blocking the flow of blood to a tumor and depriving it of oxygen and nutrients essential to its survival. Similarly, in eye diseases that are characterized by abnormal blood vessel growth, ZYBRESTAT has been shown in pre-clinical studies to suppress development and induce regression of these unnecessary blood vessels. In a Phase II proof-of-concept study with intravenous-route ZYBRESTAT in patients with myopic macular degeneration, 100% of subjects achieved the study's primary endpoint. Based on these encouraging results, OXiGENE is working to develop a patient-friendly, topical formulation of ZYBRESTAT (e.g., eye drops) for age-related macular degeneration and/or other ophthalmological indications. ZYBRESTAT is currently being evaluated in multiple human clinical trials.

Back to Top

OXi4503, a Unique, Dual-Mechanism VDA
OXiGENE believes that OXi4503 is the first in a new class of compounds known as ortho-quinone prodrugs (OQPs), which display a novel cytotoxic effect in addition to their vascular targeting capabilities mediated by their action on the tubulin cytoskeleton. Unlike anti-angiogenesis agents that focus on preventing new tumor blood vessels from forming, OQPs appear to attack existing blood vessel structures in the central regions of solid tumors and also have a cytotoxic effect that could enable destruction of the outside rim of cells that reside next to, and are dependent upon, normal tissue blood vessels. OXi4503 is currently being studied in a Phase I clinical trial.

Back to Top

The Business Model
OXiGENE's business model and structure are designed for efficiency, flexibility and investor return. OXiGENE leverages its internal drug development management expertise while utilizing external collaborations with academic institutions, pharmaceutical companies and clinical research organizations to advance the Company's clinical development and research efforts. By not investing in sizable infrastructure the Company is better able to minimize costs and achieve a lower cash burn rate. The result is a company that remains flexible to the ever-changing needs and demands of the biopharmaceutical industry environment and allows for efficient and rapid prosecution of clinical development programs.

Back to Top